CAR T-cell Therapy Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-04-24　·　168 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 4.83 Bn
2033 年預估規模: USD 18.46 Bn
年複合成長率 CAGR: 21.1%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

出版商 Coherent Market Insights 產業別 Healthcare & Life Sciences出版日期 2026-04-24頁數 168報告編號 CMI102

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

CAR T-cell Therapy Market, By Targeted Antigen (CD19, BCMA, HER2, GD2, CD20, CD22, CD30, CD33, HER1, and Others), By Therapeutic Application (Hematological Malignancies and Solid Tumors), By Therapy Type (Autologous CAR T-cell Therapy and Allogeneic CAR T-cell Therapy), By End User (Hospitals, Cancer Treatment Centers, Academic and Research Institutes, and Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

報告摘要

Chimeric antigen receptor (CAR)-T cell therapy is a type of immunotherapy which uses immune T cells to destroy cancer. CAR T cell therapy is also called as cell based gene therapy, as it involves gene altering in T cells. For chimeric antigen receptor (CAR)-T cell therapy, T cells are extracted from human body using a procedure called leukapheresis. Then after extraction, T cells are altered by adding the gene for the specific chimeric antigen receptor (CAR) and hence they are called as CAR T cells. After the alteration, the cells are kept to grow and then are infused into human body. Different type of CAR T cell therapy are made to fight specific type of cancer. CAR- T cells are customized for different patients and then infused in blood. CAR T cells therapy is used as a novel gene therapy to fight cancer. Different clinical and preclinical studies are going on to study the safety and efficacy of various CAR-T cell therapies for specific cancer. Moreover, several governments are taking initiatives such as campaigns to spread the awareness of cancer for example educational campaign by Centers for Disease Control and Prevention (CDC). Market Dynamics Increasing adoption of organic strategies by key players in market such as product approval is expected to drive market growth over the forecast period. For instance, in May 2022, Novartis AG., one of the global healthcare company, received the U.S. Food and Drug Administration approval for Kymriah (tisagenlecleucel) CAR-T cell therapy for the treatment of adult patients with relapsed or refractory follicular lymphoma. The approval is based on phase II clinical trial, evaluated with 68% of positive response from the patients. Key features of the study • This report provides in-depth analysis of the global CAR T cell therapy market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period 2026 - 2033, considering 2025 as the base year. • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market. • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players. • It profiles key players in the global CAR T cell therapy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies. • Key companies covered as a part of this study include Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Novartis AG, CARsgenTherapeutics Co.,Ltd, Aurora Biopharma, Legend Biotech, Gilead Sciences, Inc., Pfizer Inc., bluebird bio, Inc., Sorrento Therapeutics, Inc., Mustang Bio, Fate Therapeutics among other prominent players. • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics. • The global CAR T cell therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts. • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global CAR T cell therapy market. Market Segmentation • Global CAR T Cell Therapy Market, By Targeted Antigen o CD19 o BCMA o HER2 o GD2 o CD20 o CD22 o CD30 o CD33 o HER1 o Others (CLDN18, etc.) • Global CAR T Cell Therapy Market, By Therapeutic Application o Acute Lymphocytic Leukemia o Chronic Lymphocytic Leukemia o Diffuse Large B-cell Lymphoma (DLBCL) o Follicular Lymphoma o Mantle Cell Lymphoma o Multiple Myeloma o Glioblastoma o Sarcoma o Neuroblastoma o Acute Myeloid Leukemia o Breast Cancer o Pancreatic Cancer o Hepatocellular Carcinoma o Colorectal Cancer o Others (Gastric Cancer, etc.) • Global CAR T Cell Therapy Market, By Region o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC Countries  Israel  Rest of Middle East o Africa  South Africa  North Africa  Central Africa • Company Profiles o Bristol-Myers Squibb Company o Johnson & Johnson Services, Inc. o Novartis AG o CARsgenTherapeutics Co., Ltd. o Aurora Biopharma o Legend Biotech o Gilead Sciences, Inc. o Pfizer Inc. o bluebird bio, Inc. o Sorrento Therapeutics, Inc. o Mustang Bio o Fate Therapeutics

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Global CAR T-cell Therapy Market, By Targeted Antigen  Global CAR T-cell Therapy Market, By Therapeutic Application  Global CAR T-cell Therapy Market, By Therapy Type  Global CAR T-cell Therapy Market, By End User  Global CAR T-cell Therapy Market, By Region 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics o Impact Analysis o Key Highlights o Regulatory Scenario o Product Launches/Approvals o PEST Analysis o PORTER’s Analysis o Market Opportunities o Regulatory Scenario o Key Developments o Industry Trends 4. Global CAR T-cell Therapy Market, By Targeted Antigen, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o CD19  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o BCMA  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o HER2  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o GD2  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o CD20  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o CD22  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o CD30  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o CD33  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o HER1  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Others  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 5. Global CAR T-cell Therapy Market, By Therapeutic Application, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Hematological Malignancies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Solid Tumors  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 6. Global CAR T-cell Therapy Market, By Therapy Type, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Autologous CAR T-cell Therapy  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Allogeneic CAR T-cell Therapy  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 7. Global CAR T-cell Therapy Market, By End User, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Hospitals  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Cancer Treatment Centers  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Academic and Research Institutes  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Others  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 8. Global CAR T-cell Therapy Market, By Region, 2021 - 2033, Value (USD Bn) o Introduction  Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)  Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)  Regional Trends o North America  Introduction  Market Size and Forecast, By Targeted Antigen, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Therapeutic Application, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o U.S. o Canada o Latin America  Introduction  Market Size and Forecast, By Targeted Antigen, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Therapeutic Application, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o Brazil o Argentina o Mexico o Rest of Latin America o Europe  Introduction  Market Size and Forecast, By Targeted Antigen, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Therapeutic Application, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o Germany o U.K. o Spain o France o Italy o Russia o Rest of Europe o Asia Pacific  Introduction  Market Size and Forecast, By Targeted Antigen, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Therapeutic Application, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o China o India o Japan o Australia o South Korea o ASEAN o Rest of Asia Pacific o Middle East  Introduction  Market Size and Forecast, By Targeted Antigen, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Therapeutic Application, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o GCC Countries o Israel o Rest of Middle East o Africa  Introduction  Market Size and Forecast, By Targeted Antigen, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Therapeutic Application, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn) o South Africa o North Africa o Central Africa 9. Competitive Landscape o Bristol-Myers Squibb Company  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Johnson & Johnson Services, Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Novartis AG  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Gilead Sciences, Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Legend Biotech  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o bluebird bio, Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o CARsgen Therapeutics Co., Ltd.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Mustang Bio  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Fate Therapeutics  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Sorrento Therapeutics, Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies 10. Analyst Recommendations o Wheel of Fortune o Analyst View o Coherent Opportunity Map 11. References and Research Methodology o References o Research Methodology o About us *Browse 32 market data tables and 28 figures on 'CAR T-cell Therapy Market' - Global forecast to 2033

提及公司

Bristol-Myers Squibb CompanyJohnson & Johnson Services, Inc.Novartis AGCARsgenTherapeutics Co., Ltd.Aurora BiopharmaLegend BiotechGilead Sciences, Inc.Pfizer Inc.bluebird bio, Inc.Sorrento Therapeutics, Inc.Mustang BioFate Therapeutics

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們